SynBioBeta Speaker
Matt Angle
Paradromics
Founder & CEO
Matt Angle, PhD is the Founder and CEO of Paradromics, a neurotechnology leader developing the world’s most advanced and clinically viable brain-computer interface (BCI) platform—bridging human thought and digital capability. He earned his PhD in Neuroscience from the University of Heidelberg, followed by postdoctoral research at Stanford University. Paradromics engineered its first clinical product, the Connexus® BCI, received two FDA Breakthrough Device Designations, and performed the first-in-human neural recording in May 2025. The company is now preparing to launch a clinical trial in early 2026, pending regulatory approval.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Matt
This Year
•
-
Human Health
From Therapeutics to Consumer Applications: How Brain Computer Interfaces are About to Become the Next Major Platform Technology
Brain Computer Interfaces (BCIs) hold immense promise to help restore critical functions now for individuals with neurological conditions, severe speech impairments, and paralysis. Over the last thirty-five years, major advancements in artificial intelligence, brain mapping, and material sciences are laying the foundation for a future where BCI-enabled augmented experience is as common as accessing the internet or using a mobile phone. Join Paradromics CEO Matt Angle, PhD to discuss the latest on neurotechnology today, as well as expansive future BCI applications.
Get a Ticket
•
-
Human Health
From Therapeutics to Consumer Applications: How Brain Computer Interfaces are About to Become the Next Major Platform Technology
Brain Computer Interfaces (BCIs) hold immense promise to help restore critical functions now for individuals with neurological conditions, severe speech impairments, and paralysis. Over the last thirty-five years, major advancements in artificial intelligence, brain mapping, and material sciences are laying the foundation for a future where BCI-enabled augmented experience is as common as accessing the internet or using a mobile phone. Join Paradromics CEO Matt Angle, PhD to discuss the latest on neurotechnology today, as well as expansive future BCI applications.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
